Close

Ligand Pharma (LGND) Announces Publishing of Results from Phase 1 Trials with LGD-6972 in Type 2 Diabetes Mellitus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. ENPH
3. TXN
4. BA
5. SPOT
6. META
7. IBM
8. V
9. KMB
10. MSFT


Go back to Ligand Pharma (LGND) Announces Publishing of Results from Phase 1 Trials with LGD-6972 in Type 2 Diabetes Mellitus